Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B (2018) Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight 3(17):e121497. doi: 10.1172/jci.insight.121497
Objective: To investigate the suitability of a CD46 antibody as a metastatic castration-resistant prostate cancer (mCRPC) anti-tumor agent.
Summary: CD46 is an excellent candidate for antibody-based therapy development, which has potential to be applicable to both adenocarcinoma and neuroendocrine types of mCRPC that are resistant to current treatment.
Usage: Biotinylated UA20 IgG and Streptavidin-ZAP were mixed at a molar ratio of 1:1. The conjugate was used in cytotoxicity assays and shown to specifically kill the mCRPC cells.
Related Products: Streptavidin-ZAP (Cat. #IT-27)